Telix Pharmaceuticals (TLX) Enterprise Value (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Enterprise Value for 3 consecutive years, with -$141.9 million the latest figure, recorded in Q4 2025.

• Quarterly Enterprise Value rose 71.72% year-over-year to -$141.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$141.9 million (up 71.72% YoY) and the FY2025 annual result came in at -$141.9 million, up 71.72% from the prior year.
• Enterprise Value rose to -$141.9 million in Q4 2025 per TLX's latest filing, from -$501.7 million in the prior quarter.
• Over the last five years, Enterprise Value for TLX reached as high as -$87.0 million in Q4 2023 and fell as low as -$501.7 million in Q4 2024.
• A 3-year average of -$243.5 million and a median of -$141.9 million in 2025 frame the typical range for Enterprise Value.
• Annual changes were most pronounced in 2024 — Enterprise Value tumbled 476.41% — and 2025, when it jumped 71.72%.
• Year by year, Enterprise Value stood at -$87.0 million in 2023, then slumped by 476.41% to -$501.7 million in 2024, then soared by 71.72% to -$141.9 million in 2025.
• According to Business Quant data, Enterprise Value over the past three periods registered -$141.9 million, -$501.7 million, and -$87.0 million for Q4 2025, Q4 2024, and Q4 2023 respectively.